Clinical Trials Logo

Systemic Lupus clinical trials

View clinical trials related to Systemic Lupus.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04894253 Recruiting - Systemic Lupus Clinical Trials

Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus

LUPCELLVAX
Start date: June 7, 2021
Phase:
Study type: Observational [Patient Registry]

The main objective is to study the impact of vaccination against Covid-19 on the specific humoral and cellular immune response (against SARS-CoV-2) and non-specific (evolution of the pathological immune system of the disease), in a lupus population. The secondary objective is to study the impact of lupus disease activity on the humoral and cellular response of patients following vaccination against SARS-CoV-2. The hypothesis is that disease activity and / or certain treatments used in lupus may interfere with the humoral and cellular immune response induced by vaccination against SARS-CoV-2.

NCT ID: NCT03819777 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)

VOC-PAH
Start date: March 1, 2018
Phase:
Study type: Observational

Aim: to investigate the role of inflammation and auto-immunity in pulmonary arterial hypertension by using the profile of volatile organic compounds. Hypothesis: first, the investigators hypothesize that at time of diagnosis the VOC profiles will discriminate patients with PAH-CTD and idiopathic PAH (IPAH) from patients with systemic sclerosis or systemic lupus erythematosus (CTD) without PAH, supporting the contention that there is a overlapping inflammatory and auto-immune pathway in PAH. During follow-up, the investigators will measure the VOC profiles of patients in all three groups who will be treated according standard clinical care. The hypothesis is that VOC profiles are affected by therapy.